JP2021527128A5 - - Google Patents

Info

Publication number
JP2021527128A5
JP2021527128A5 JP2021518056A JP2021518056A JP2021527128A5 JP 2021527128 A5 JP2021527128 A5 JP 2021527128A5 JP 2021518056 A JP2021518056 A JP 2021518056A JP 2021518056 A JP2021518056 A JP 2021518056A JP 2021527128 A5 JP2021527128 A5 JP 2021527128A5
Authority
JP
Japan
Prior art keywords
subject
product according
pharmaceutical product
mkh2
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527128A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036138 external-priority patent/WO2019237053A1/en
Publication of JP2021527128A publication Critical patent/JP2021527128A/ja
Publication of JP2021527128A5 publication Critical patent/JP2021527128A5/ja
Priority to JP2024043503A priority Critical patent/JP7847880B2/ja
Pending legal-status Critical Current

Links

JP2021518056A 2018-06-08 2019-06-07 組織石灰化を予防または治療するための方法および組成物 Pending JP2021527128A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024043503A JP7847880B2 (ja) 2018-06-08 2024-03-19 組織石灰化を予防または治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682796P 2018-06-08 2018-06-08
US62/682,796 2018-06-08
PCT/US2019/036138 WO2019237053A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating tissue calcification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024043503A Division JP7847880B2 (ja) 2018-06-08 2024-03-19 組織石灰化を予防または治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2021527128A JP2021527128A (ja) 2021-10-11
JP2021527128A5 true JP2021527128A5 (enExample) 2022-06-10

Family

ID=68765387

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518056A Pending JP2021527128A (ja) 2018-06-08 2019-06-07 組織石灰化を予防または治療するための方法および組成物
JP2024043503A Active JP7847880B2 (ja) 2018-06-08 2024-03-19 組織石灰化を予防または治療するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024043503A Active JP7847880B2 (ja) 2018-06-08 2024-03-19 組織石灰化を予防または治療するための方法および組成物

Country Status (11)

Country Link
US (8) US10688064B2 (enExample)
EP (1) EP3801477A4 (enExample)
JP (2) JP2021527128A (enExample)
KR (1) KR20210018423A (enExample)
CN (1) CN113038940A (enExample)
AU (1) AU2019282420B2 (enExample)
CA (1) CA3102977A1 (enExample)
IL (1) IL279245B2 (enExample)
MX (2) MX2020013302A (enExample)
SG (1) SG11202012070YA (enExample)
WO (1) WO2019237053A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
IL279245B2 (en) 2018-06-08 2024-03-01 Epizon Pharma Inc Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification
WO2020055678A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
MX2021010977A (es) * 2019-03-12 2021-12-10 Nattopharma As Uso de vitamina k en combinacion con anticoagulantes.
KR20240045216A (ko) * 2021-07-05 2024-04-05 위니베르시테이트 마스트리흐트 칼슘 결정 침착 질환의 치료 수단 및 방법
WO2023129413A1 (en) * 2021-12-31 2023-07-06 Ingredient Fusion, Llc Molecular complexing method, formulation and manufacturing for enhanced nutrient delivery
WO2024071848A1 (ko) * 2022-09-27 2024-04-04 경북대학교 산학협력단 혈관석회화 치료제 스크리닝 방법
WO2025075468A1 (ko) * 2023-10-06 2025-04-10 주식회사 레드엔비아 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
WO2005030190A1 (en) * 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
SI1728507T1 (sl) 2005-06-03 2011-07-29 Nattopharma Asa Uporaba vitamina K za reverziranje kalcifikacije krvnih Ĺľil
EP2046312B1 (en) * 2006-07-14 2020-02-19 Kaydence Pharma AS Pharmaceutical and nutraceutical products comprising vitamin k2
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
WO2012059942A2 (en) 2010-11-01 2012-05-10 Viridis Biopharma Pvt. Ltd Dynamic balancing of autonomic nervous system through vitamin mk-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
ES2869202T3 (es) 2012-06-18 2021-10-25 Fresenius Kabi Deutschland Gmbh Sistema de cánula para vía para la punción de vías centrales de acceso subcutáneo
WO2014191466A1 (en) 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function
MX2017011934A (es) 2015-03-20 2018-02-09 Gnosis Spa Formas solidas de menaquinoles.
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
IL279245B2 (en) 2018-06-08 2024-03-01 Epizon Pharma Inc Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification

Similar Documents

Publication Publication Date Title
JP2021527128A5 (enExample)
JP2021527129A5 (enExample)
Shek et al. Statin—fibrate combination therapy
Kurban et al. Cutaneous manifestations of chronic kidney disease
Wang et al. Effects of atorvastatin on chronic subdural hematoma: a preliminary report from three medical centers
JP2022554020A5 (enExample)
Sauder et al. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis
JP7578243B2 (ja) アルカリ性化剤による血液浄化
JP2016538277A5 (enExample)
CN113038940A (zh) 用于预防或治疗组织钙化的方法和组合物
Hiramoto et al. Evidence-based analysis: postoperative gastric bleeding: etiology and prevention
Wang et al. Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement
JP2018516931A5 (enExample)
RU2447913C1 (ru) Способ лечения местнораспространенного рака молочной железы с опухолевыми изъязвлениями кожи
Qian et al. Effect of Pingchuan Guben decoction on patients with chronic obstructive pulmonary disease: Results from a randomized comparative effectiveness research trial
EP3969110A1 (en) Compositions comprising 15-hepe and/or 15-hetre and methods of treating or preventing cardiometabolic disease, metabolic syndrome, and/or related diseases
RU2465905C2 (ru) Способ замедления преждевременного старения у работников газодобывающего предприятия
JP6184960B2 (ja) メラトニンの新規用途
Yahya et al. Old drug with new milestone: chloroquine and hydroxychloroquine in SARS-COV-2 (COVID-19) with multifaceted effects in other diseases
WO2017180259A1 (en) Methods for treating nsaid-induced cardiovascular, cerebrovascular, or renovascular adverse events
ROCHA et al. Functional nutrition in postoperative plastic surgery: focus on seroma and fibrosis prevention
Ballantyne et al. 1084-176 Efficacy of ezetimibe coadministered with simvastatin versus atorvastatin in patients with hypercholesterolemia
HINT FICA: Taking a Spiritual History
CN101766618A (zh) 匹伐他汀钙的新用途以及针对新用途的药物
Breijo-Marquez Inadequate Use of the Drug Acenocoumarol in Non-Valvular Atrial Fibrillation